# A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS

> **NCT00375284** · PHASE4 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 404 (actual)

## Conditions studied

- Restless Legs Syndrome

## Interventions

- **DRUG:** Pramipexole

## Key facts

- **NCT ID:** NCT00375284
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2007-07
- **Final completion:** —
- **Target enrollment:** 404 (ACTUAL)
- **Last updated:** 2013-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00375284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00375284, "A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00375284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*